Targeting FLT3 by chimeric antigen receptor T cells for the treatment of acute myeloid leukemia
Authors:
Open Access
- 12 May 2017
- journal article
- letter
- Published by Springer Nature in Leukemia
- Vol. 31 (8) , 1830-1834
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem CellsScientific Reports, 2015
- Chimeric Antigen Receptor T Cells for Sustained Remissions in LeukemiaNew England Journal of Medicine, 2014
- Genetic Modification of T Cells Redirected toward CS1 Enhances Eradication of Myeloma CellsClinical Cancer Research, 2014
- Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cellsBlood, 2014
- CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myelomaLeukemia, 2013
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid LeukemiaNew England Journal of Medicine, 2013
- Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007Blood, 2012
- FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studyBlood, 2010
- CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsetsBlood, 2010
- Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.2001